25 Jul 2024 - Ad Hoc announcement pursuant to Art. 53 LR
Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
- Lonza delivered sales of CHF 3.1 billion, growing 1.8%1 CER
- CHF 893 million CORE EBITDA resulted in a margin of 29.2%
- Robust performance in CDMO business, with headwinds in the capsules business within the Capsules & Health Ingredients (CHI) division
- Solid free cash flow at CHF 296 million
- Group Outlook 2024 confirmed: flat CER sales growth and CORE EBITDA margin in high twenties
- Mid-Term Guidance 2024 – 2028, upgraded in March, confirmed
Group Financial Summary
| CHF million |
| HYR 2024 |
| YoY change (in %) |
| HYR 2023 |
| Sales in AER |
| 3,057 |
| (0.7) |
| 3,078 |
| EBITDA |
| 862 |
| (4.1) |
| 899 |
| Margin in % |
| 28.2 |
|
|
| 29.2 |
| CORE EBITDA |
| 893 |
| (3.1) |
| 922 |
| Margin in % |
| 29.2 |
|
|
| 30.0 |
For more details on performance and financials, please refer to the Half-Year 2024 Presentation, Half-Year 2024 Report and Alternative Performance Measures (APM) 2024 Report.
1 Sales growth figures, expressed as a percentage (%), are at Constant Exchange Rate (CER)
2 Actual Exchange Rate
Downloads